US Bancorp DE Has $83,000 Holdings in Geron Co. (NASDAQ:GERN)

US Bancorp DE increased its holdings in shares of Geron Co. (NASDAQ:GERN) by 68.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 18,296 shares of the biopharmaceutical company’s stock after buying an additional 7,429 shares during the quarter. US Bancorp DE’s holdings in Geron were worth $83,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of GERN. Vanguard Group Inc. lifted its position in Geron by 4.6% during the 1st quarter. Vanguard Group Inc. now owns 29,869,287 shares of the biopharmaceutical company’s stock worth $98,569,000 after buying an additional 1,304,713 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Geron in the 2nd quarter valued at approximately $106,185,000. Farallon Capital Management LLC increased its position in Geron by 124.6% during the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after purchasing an additional 9,342,000 shares in the last quarter. Affinity Asset Advisors LLC bought a new position in Geron in the 1st quarter valued at approximately $8,250,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Geron by 999.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after acquiring an additional 1,877,184 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. HC Wainwright started coverage on shares of Geron in a research report on Tuesday, November 5th. They set a “buy” rating and a $8.00 price objective for the company. Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Geron in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Geron in a report on Friday, August 9th. Finally, Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.05.

Geron Stock Down 1.3 %

GERN opened at $3.66 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. Geron Co. has a 12 month low of $1.64 and a 12 month high of $5.34. The company has a market cap of $2.21 billion, a P/E ratio of -11.44 and a beta of 0.52. The business’s 50-day moving average price is $4.26 and its 200-day moving average price is $4.31.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. Geron’s revenue was up 17138.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) earnings per share. On average, equities analysts expect that Geron Co. will post -0.25 EPS for the current year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.